Join the Dupixent group to help and get support from people like you.
Dupixent News (Page 2)
FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for use with other medicines to treat chronic rhinosinusitis...
FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for adolescent patients 12 to 17 years of age with...
FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma
PARIS and TARRYTOWN, N.Y., Oct. 19, 2018 /PRNewswire/ – Sanofi (EURONEXT: SAN) (NYSE: SNY) The U.S. Food and Drug Administration has approved Dupixent® (dupilumab) as an add-on maintenance therapy ...
FDA Approves Dupixent (dupilumab) for Eczema
March 28, 2017 – The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for...
Further information
Related condition support groups
Asthma - Maintenance, Contact Dermatitis, Atopic Dermatitis, Eczema